Application of PEG-interferon and protooncogene product targeting inhibitor in synergistic inhibition of tumors

A method for treatment of a tumor, comprising a step of:

• administering a combination of active ingredients to a subject in need thereof, wherein the active ingredients comprises a first active ingredient of polyethylene glycol (PEG)-interferon and a second active ingredient of a protooncogene product targeting inhibitor;
• wherein the PEG-interferon is a PEG-interferon α1b;
• the protooncogene product targeting inhibitor is selected from the group consisting of:
• Bevacizumab, Trastuzumab, and combinations thereof;
• when the protooncogene product targeting inhibitor is Bevacizumab, the tumor comprises gastric or liver cancer;
• when the protooncogene product targeting inhibitor is Trastuzumab, the tumor comprises breast cancer;
• wherein the dose of the PEG-interferon is 50 ng/kg body weight to 10 mg/kg body weight, and the dose of the protooncogene product targeting inhibitor is 50 ng/kg body weight to 10 mg/kg body weight;
• and wherein the PEG-interferon is administered to the subject before, during and/or after the administration of the protooncogene product targeting inhibitor.